Acetylator status, drug metabolism and disease

National Medical Journal of India

Volumn 16, Issue 1, 2003, Pages 24-26

  Pande, J N ^a   Pande, A ^b   Singh, S P N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; AMINOGLUTETHIMIDE; AMINOSALICYLIC ACID; AROMATIC AMINE; CARBAMAZEPINE; CARCINOGEN; DAPSONE; HYDRALAZINE; HYDRAZINE DERIVATIVE; ISONIAZID; PHENYTOIN; PROCAINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; SULFONAMIDE; TOBACCO SMOKE; XENOBIOTIC AGENT;

ACETYLATION; ACETYLATOR PHENOTYPE; ALLELE; BREAST CANCER; CIGARETTE SMOKING; COLORECTAL CANCER; CYTOSOL; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIVER DISEASE; LIVER METABOLISM; LUNG CANCER; LUPUS VULGARIS; MOLECULAR GENETICS; PERIPHERAL NEUROPATHY; REVIEW; TOXICOKINETICS;

ACETYLATION; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; COLORECTAL NEOPLASMS; GENOTYPE; HUMANS; ISONIAZID; LUPUS; PERIPHERAL NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 0345269074     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci 1991;88:5237-41.
2. Zhao B, Seow A, Lee EJ, Lee HP. Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 2000;56:689-92.
3. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-92.
4. Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, et al. N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 2001;5:544-9.
5. Wolkenstein P, Loriot MA, Aractingi S, Cabelguenne A, Beaune P, Chosidow O. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS. Pharmacogenetics 2000;10:821-8.
6. O'Neil WM, Drobitch RK, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, et al. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000;10:171-82.
7. Singh SPN, Pande JN, Khilnani GC, Kailash S. Comparison between serum and urinary sulphadimidine acetylators as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis. Indian J Chest Dis Allied Sci 1996;38:5-11.
8. Ellard GA. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin Pharmacol Ther 1976;19:610-25.
9. Hombhanje F. An assessment of acetylator polymorphism and its relevance in Papua New Guinea. PNG Med Jour 1990;33:107-10.
10. Hildebrand M, Seifert W. Determination of acetylator phenotype in Caucasians with caffeine. Eur J Clin Pharmacol 1989;37:525-6.
11. Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S. N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics 1998;8:291-8.
12. Bach PH, Higgins-Opitz SB, Bima B, Leary WP. Isoniazid acetylator status of Black South African tuberculosis patients. S Afr Med J 1976;50:1132-4.
13. Pande JN, Singh SPN, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from anti-tuberculosis drugs: A case-control study. Thorax 1996;50:132-6.
14. Brockton N, Little J, Sharp L, Cotton SC. N-acetyltransferase polymorhisms and colorectal cancer: A HuGe review. Am J Epidemiol 2000;151:846-61.
15. Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191-6.
16. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, et al. Hepatic toxicity in south Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986;67:99-108.
17. Gurumurthy P, Krishnamurthy MS, Nazareth O, Parthasarathy R, Sarma GR, Somasunderan PR, et al. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984;129:58-61.
18. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis. Br J Gastroenterol Hepatol 1997;12:87-91.
19. Clark DW. Genetically determined variability in acetylation and oxidation: Therapeutic implications. Drugs 1985;29:342-75.
20. Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JE, Skovsted L, et al. Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 1985;20:323-6.
21. Kitas GD, Farr M, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:220-5.
22. Spielberg SP. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug metabolism. J Pharmacokinet Biopharm 1996;24:509-19.
23. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29-42.
24. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: A meta-analysis. Environ Mol Mutagen 2000;36:221-7.
25. Green J, Banks E, Berrington A, Darby S, Deo H, Newton R. N-acetyltransferase 2 and bladder cancer: An overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000;83:412-17.
26. Welfare MR, Cooper J, Bassendine MF, Daly AK. Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997;18:1351-4.
27. Deitz AC, Zheng W, Leff MA, Gross M, Wen WQ, Doll MA, et al. N-acetyltransferase-2 genetic polymorphism, well-done meat intake, and breast cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2000;9:905-10.
28. Seow A, Zhao B, Poh WT, Teh M, Eng P, Wang YT, et al. NAT2 slow acetylator genotype is associated with increased risk of lung cancer among non-smoking Chinese women in Singapore. Carcinogenesis 1999;20:1877-81.
29. Oyama T, Kawamoto T, Mizoue T, Yasumoto K, Kodama Y, Mitsudomi T. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 1997;17:577-81.
30. Katoh T, Kaneko S, Boissy R, Watson M, Ikemure K, Bell DA, et al. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis 1998;19:1803-7.